Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRIONASDAQ:FEMYNASDAQ:PYPDNASDAQ:STRR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$0.72+0.3%$0.68$0.50▼$1.73$31.64M1.55278,052 shs94,056 shsFEMYFemasys$1.04-1.9%$1.21$0.86▼$1.80$28.33M-2.52236,889 shs45,639 shsPYPDPolyPid$2.78-0.4%$2.71$2.30▼$4.67$28.33M1.2516,481 shs16,092 shsSTRRStar Equity$2.00-2.9%$2.18$1.72▼$5.35$6.42M0.8718,025 shs30,980 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth0.00%+9.09%-12.20%+4.35%-58.62%FEMYFemasys0.00%-1.89%-16.13%-36.78%-20.00%PYPDPolyPid0.00%+1.42%+4.47%-7.06%-40.30%STRRStar Equity0.00%-13.42%+0.50%-8.68%-55.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRIODarioHealth1.8616 of 5 stars3.31.00.00.02.40.81.3FEMYFemasys2.0085 of 5 stars3.53.00.00.00.02.50.6PYPDPolyPid1.5642 of 5 stars3.63.00.00.00.01.70.0STRRStar Equity3.1486 of 5 stars3.55.00.00.01.81.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRIODarioHealth 2.67Moderate Buy$2.00177.78% UpsideFEMYFemasys 3.00Buy$8.67733.33% UpsidePYPDPolyPid 3.25Buy$11.33307.82% UpsideSTRRStar Equity 3.00Buy$5.00150.00% UpsideCurrent Analyst Ratings BreakdownLatest STRR, DRIO, PYPD, and FEMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025DRIODarioHealthLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/15/2025STRRStar EquityMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.004/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/28/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/19/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.003/13/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/11/2025DRIODarioHealthStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $2.002/26/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRIODarioHealth$28.03M1.13N/AN/A$2.14 per share0.34FEMYFemasys$1.70M16.67N/AN/A$0.85 per share1.22PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ASTRRStar Equity$57.17M0.11$0.33 per share6.11$14.63 per share0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRIODarioHealth-$59.43M-$0.56N/AN/AN/A-205.62%-72.16%-40.74%N/AFEMYFemasys-$14.25M-$0.91N/AN/AN/A-1,435.77%-141.49%-82.30%N/APYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-624.10%-129.28%8/13/2025 (Estimated)STRRStar Equity$25.13M-$3.43N/AN/AN/A-12.41%-8.72%-4.62%8/12/2025 (Estimated)Latest STRR, DRIO, PYPD, and FEMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DRIODarioHealth-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 million5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A5/14/2025Q1 2025STRRStar Equity-$0.25-$0.52-$0.27-$0.37$16.35 million$12.92 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million3/27/2025Q4 2024FEMYFemasys-$0.25-$0.23+$0.02-$0.23$1.66 million$0.58 million3/20/2025Q4 2024STRRStar Equity-$0.17$0.15+$0.32-$0.94$14.00 million$17.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRIODarioHealthN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRIODarioHealth0.351.571.32FEMYFemasys0.863.943.26PYPDPolyPid0.081.311.00STRRStar Equity0.212.051.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRIODarioHealth33.39%FEMYFemasys65.27%PYPDPolyPid26.47%STRRStar Equity3.84%Insider OwnershipCompanyInsider OwnershipDRIODarioHealth10.90%FEMYFemasys12.32%PYPDPolyPid24.70%STRRStar Equity33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRIODarioHealth20043.95 million28.47 millionOptionableFEMYFemasys3027.24 million20.08 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataSTRRStar Equity4603.21 million2.14 millionNot OptionableSTRR, DRIO, PYPD, and FEMY HeadlinesRecent News About These CompaniesSTAR EQUITY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Star Equity ...May 24 at 11:15 PM | morningstar.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Star Equity Holdings, Inc. (NASDAQ: STRR)May 24 at 8:28 AM | financialpost.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Star Equity Holdings, Inc. (NASDAQ: STRR)May 24 at 8:28 AM | financialpost.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Star Equity Holdings, Inc. (NASDAQ: STRR)May 24 at 8:08 AM | globenewswire.comStar Equity Q4 EPS Lowered by Litchfield Hills ResearchMay 24 at 2:43 AM | americanbankingnews.comSTAR EQUITY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Star Equity Holdings, Inc. - STRRMay 22 at 7:37 PM | businesswire.comStar Equity Holdings, Inc. Declares Cash Dividend of $0.25 for Preferred StockholdersMay 22 at 4:41 AM | nasdaq.comHudson Global, Inc.: Star Equity Holdings and Hudson Global Sign Definitive Merger AgreementMay 22 at 4:41 AM | finanznachrichten.deSTRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Star Equity Holdings, Inc. Is Fair to ShareholdersMay 21, 2025 | businesswire.comStar Equity Holdings, Inc. and Hudson Global, Inc. Announce Definitive Merger Agreement to Form NewCoMay 21, 2025 | quiverquant.comStar Equity Holdings, Inc. and Hudson Global, Inc. Announce Merger Agreement to Form NewCoMay 21, 2025 | quiverquant.comStar Equity Holdings and Hudson Global Sign Definitive Merger AgreementMay 21, 2025 | globenewswire.comStar Equity Holdings Declares Cash Dividend for Preferred StockMay 20, 2025 | tipranks.comStar Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred StockMay 20, 2025 | globenewswire.comMaxim Group Issues Pessimistic Forecast for Star Equity (NASDAQ:STRR) Stock PriceMay 17, 2025 | americanbankingnews.comStar Equity signals record $27.9M backlog while advancing Energy Services integrationMay 15, 2025 | msn.comStar Equity Holdings Inc (STRR) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 15, 2025 | finance.yahoo.comStar Equity Holdings, Inc. (NASDAQ:STRR) Q1 2025 Earnings Call TranscriptMay 15, 2025 | insidermonkey.comStar Equity Holdings, Inc. (STRR) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comStar Equity (STRR) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTRR, DRIO, PYPD, and FEMY Company DescriptionsDarioHealth NASDAQ:DRIO$0.72 +0.00 (+0.28%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.72 0.00 (-0.14%) As of 05/23/2025 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Femasys NASDAQ:FEMY$1.04 -0.02 (-1.89%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.04 0.00 (0.00%) As of 05/23/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.PolyPid NASDAQ:PYPD$2.78 -0.01 (-0.39%) Closing price 05/23/2025 03:50 PM EasternExtended Trading$2.78 +0.00 (+0.04%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Star Equity NASDAQ:STRR$2.00 -0.06 (-2.91%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$2.04 +0.04 (+2.25%) As of 05/23/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver This Market Sell-Off Might Trigger a Value Rotation Into Pepsi Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
